RBP3 Antibody

Basic Research Questions

• What is RBP3 and why is it important in retinal research?

RBP3, also known as Interphotoreceptor Retinoid-Binding Protein (IRBP), is a large glycoprotein (approximately 135kDa) synthesized and secreted primarily by rod photoreceptor cells into the interphotoreceptor matrix. It plays a crucial role in the visual cycle by shuttling 11-cis and all-trans retinoids between the retinol isomerase in the pigment epithelium and the visual pigments in the photoreceptor cells .

RBP3 has gained significant research interest because:

• It facilitates the movement of molecules necessary for the visual cycle

• It ensures efficient communication between different cellular components of the eye

• It aids in the regeneration of visual pigments and the function of photosensitive cells

• Recent studies have shown its protective role against diabetic retinopathy, independent of glycemic control

• What applications are RBP3 antibodies commonly used for?

Based on validated data from multiple commercial sources and research publications, RBP3 antibodies are successfully used in:

When selecting an application, researchers should consider that WB consistently shows the highest validation rates across different RBP3 antibodies .

• What is the expected molecular weight pattern of RBP3 in Western blots?

The expected canonical molecular weight of RBP3 is approximately 135 kDa, but multiple molecular weight bands are frequently observed in experimental samples:

• The full-length protein typically appears at 135-140 kDa

• Multiple additional bands have been consistently reported at 25, 40, 60, and 80 kDa

• The ratio of non-135 kDa to total bands increases in disease states, particularly in diabetic retinopathy progression

Research by the Joslin Medalist Study showed that immunoblot analysis with polyclonal antibodies made against human RBP3 revealed multiple bands in addition to the expected 135-kDa band in the vitreous of both non-diabetic controls and diabetic patients with various grades of retinopathy . This pattern appears to have biological significance rather than representing non-specific binding.

Intermediate Research Questions

• How should RBP3 antibodies be validated for specificity and reproducibility?

Proper validation of RBP3 antibodies requires a multi-faceted approach:

Primary Validation Methods:

• Knockout/Knockdown Controls: Compare Western blot results between wild-type and RBP3-knockdown samples (e.g., using shRNA targeting endogenous RBP3)

• Blocking Peptide Competition: Pre-incubate antibody with immunizing peptide to confirm signal specificity

• Multiple Antibody Comparison: Use antibodies raised against different epitopes of RBP3 to confirm consistency in detection patterns

Secondary Validation Methods:

• Recombinant Protein Controls: Test antibody against recombinant RBP3 protein fragments with defined molecular weights

• Species Cross-Reactivity Testing: Confirm expected species reactivity based on homology analysis

• Application-Specific Controls: For IHC/IF, include both primary antibody omission and isotype controls

Research has shown that antibodies recognizing different RBP3 epitopes may yield varying banding patterns. For example, one study demonstrated that a polyclonal antibody recognizing human RBP3 detected bands at 135 kDa, 80 kDa, and lower molecular weights in retinal samples, with the proportion of these bands changing in disease states .

• What factors affect the multiple banding patterns observed with RBP3 antibodies?

The multiple banding patterns observed when using RBP3 antibodies are affected by both biological and methodological factors:

Biological Factors:

• Disease State: The ratio of non-135kDa/total bands increases progressively from non-diabetic controls to proliferative diabetic retinopathy (PDR)

• Tissue Source: Vitreous samples tend to show more complex banding patterns than retinal tissue extracts

• Proteolytic Processing: RBP3 undergoes natural processing in vivo, with a 40 kDa fragment becoming predominant one day after intravitreal injection

Methodological Factors:

• Sample Preparation: Differences in protein extraction protocols significantly impact observed patterns

• Antibody Epitope: Antibodies targeting different regions of RBP3 may recognize different fragments

• Gel Conditions: Resolution of high molecular weight proteins requires specific gel concentration and running conditions

In experimental settings, researchers observed that after intravitreal injection of recombinant human RBP3, multiple protein bands at 25, 40, 60, 80, and 135 kDa were detected at 10 minutes, but after 1 day, a major band was present primarily at 40 kDa . This suggests dynamic processing of RBP3 in vivo that must be considered when interpreting Western blot results.

• How do different RBP3 antibody clones vary in their epitope specificity?

Commercial and research RBP3 antibodies target various epitopes across the protein, affecting their detection properties:

Epitope location can significantly impact experimental outcomes. For example:

• N-terminal targeting antibodies may detect a broader range of fragments

• C-terminal targeting antibodies may miss processed forms lacking this region

• Different epitopes show varying accessibility in fixed tissues for IHC applications

Advanced Research Questions

• What are the optimal protocols for detecting RBP3 in ocular fluid samples?

Detection of RBP3 in ocular fluid samples (aqueous humor, vitreous) requires specialized protocols due to limited sample volumes and variable protein concentrations:

Recommended Protocol for Vitreous Samples:

• Sample Collection: Collect undiluted vitreous (100-200 μL) during vitrectomy or from post-mortem eyes within 24 hours

• Sample Processing: Centrifuge at 12,000g for 10 minutes at 4°C to remove cellular debris

• Protein Quantification: Use micro BCA protein assay to determine total protein

• Western Blot Analysis:

  • Load 10-20 μg total protein per lane

  • Use gradient gels (4-12% or 4-20%) for optimal resolution of multiple RBP3 fragments

  • Transfer to PVDF membranes (preferred over nitrocellulose for RBP3)

  • Block with 5% milk in TBS-T for 1 hour at room temperature

  • Incubate with primary RBP3 antibody (1:1000-1:2000) overnight at 4°C

  • Visualize using chemiluminescence detection systems

For ELISA Quantification:

• Commercial RBP3 ELISA kits show variable sensitivity; validation with spike-recovery is essential

• For research studies, a sandwich ELISA using antibodies targeting different RBP3 epitopes provides more reliable quantification

Studies have shown that aqueous RBP3 levels vary significantly with disease state, with median concentrations of 2.1 nmol/L in eyes with no diabetic retinopathy decreasing to 1.5 nmol/L in eyes with mild-to-moderate nonproliferative diabetic retinopathy . This necessitates sensitive detection methods for accurate quantification.

• How can RBP3 antibodies be used to investigate RBP3's role in diabetic retinopathy?

Recent research has identified RBP3 as a potential protective factor against diabetic retinopathy progression, making antibody-based detection methods crucial for investigating this relationship:

Research Applications:

• Longitudinal Analysis: Track RBP3 levels and fragmentation patterns in aqueous/vitreous samples as disease progresses

• Immunolocalization Studies:

  • Use IHC/IF to map RBP3 expression changes in retinal layers

  • Co-staining with cell-type markers (e.g., rod-specific, vascular markers) to identify affected cells

• Protein-Protein Interaction Analysis:

  • Co-immunoprecipitation using RBP3 antibodies to identify binding partners

  • Particularly useful for studying RBP3 interactions with VEGF and GLUT1

• Fragment-Specific Detection:

  • Use antibodies targeting different epitopes to measure specific fragment profiles

  • The ratio of non-135kDa/total RBP3 forms correlates with disease severity

Methodological Considerations:

• When analyzing diabetic samples, include appropriate non-diabetic controls matched for age

• Pre-analytical variables (e.g., sample storage time, freeze-thaw cycles) significantly affect RBP3 measurements

• Standardization of detection methods is critical for multi-center studies

Research has demonstrated that elevated RBP3 levels are associated with no diabetic macular edema history (β = −0.701, 95% CI −1.151 to 0.250, P = 0.002) and less subsequent diabetic retinopathy progression (odds ratio 0.51, 95% CI 0.28–0.93, P = 0.03) . These findings suggest RBP3 may be the first neuroretinal-specific biomarker of diabetic macular edema or diabetic retinopathy progression.

• How can post-translational modifications of RBP3 be detected with specific antibodies?

Detecting post-translational modifications (PTMs) of RBP3 requires specialized antibodies and techniques:

Common RBP3 PTMs of Research Interest:

• Glycosylation: RBP3 is a glycoprotein with multiple N-glycosylation sites

• Proteolytic Processing: Multiple fragments observed in vivo suggest regulated proteolysis

• Lactylation: Recent evidence suggests lactylation may regulate RBP3 function

• Phosphorylation: May affect binding properties and interactions

Recommended Approaches:

• Modification-Specific Antibodies:

  • Use antibodies specifically targeting modified RBP3 epitopes

  • For lactylation studies, paired antibodies for modified/unmodified sites improve interpretation

• Enrichment Strategies:

  • Use lectin affinity chromatography to enrich glycosylated forms before antibody detection

  • Immunoprecipitate RBP3 first, then probe with PTM-specific antibodies (e.g., anti-phospho, anti-lactyl-lysine)

• Mass Spectrometry Validation:

  • Confirm antibody-detected modifications with LC-MS analysis

  • Essential for identifying exact modification sites

• Site-Directed Mutagenesis Controls:

  • Express wild-type versus modification site mutants (e.g., K76R for lactylation studies)

  • Use as controls for validating modification-specific antibody specificity

Recent investigations have employed liquid chromatography-mass spectrometry (LC-MS) to identify lactylation-modified sites of proteins (e.g., IGF2BP3 at K76) . Similar approaches could be applied to RBP3, with antibody-based methods used for subsequent routine detection of these modifications.

• What considerations are important when using RBP3 antibodies in experimental autoimmune uveoretinitis (EAU) models?

Researchers studying EAU models must consider several factors when using RBP3 antibodies:

Model-Specific Considerations:

• Epitope Specificity:

  • In C57BL/6J mice, RBP3 subunits 1, 2, and 3 can induce EAU, with subunit 3 eliciting the most severe disease

  • The RBP3 peptide 629-643 has been identified as a major uveitogenic peptide

  • Antibodies recognizing these specific regions may have different utility in EAU studies

• Cross-Reactivity:

  • Ensure antibodies can distinguish between murine and human RBP3 when appropriate

  • For studies involving transgenic mice expressing human RBP3 (hRBP3), species-specific antibodies are essential

• Timing of Analysis:

  • RBP3 expression changes dynamically during EAU progression

  • Multiple timepoints should be analyzed for comprehensive evaluation

Methodological Recommendations:

• For tracking epitope spreading between RBP3 peptides, use paired antibodies specific to different epitopes

• In flow cytometry applications, include careful gating strategies to identify RBP3-specific T cell populations

• For immunohistochemistry of EAU eyes, specialized fixation protocols may be required to preserve epitope accessibility

Research has shown that immunization with a single pathogenic peptide (e.g., RBP3 629-643) leads to intramolecular epitope spreading to other regions (e.g., 1-20), and this can be detected using appropriate antibodies . Understanding these dynamics is crucial for interpreting results in EAU research.